Project Description

Peter A. Jensen, MFA

President & CEO
eCAM Biomed Global Impact Investment Management Limited (Guernsey)

President & CEO
eCAM Biomed Global Impact Limited
(United Kingdom)

ECAM Therapeutics AS

Innovator. Leader. Collaborator. Entrepreneur. Biologist. Inventor. Producer. Mr. Jensen is a high-performance CEO and business manager with extensive expertise in life sciences, computer sciences, mobile, multimedia, entertainment, fintech, finance and distributed ledger technology. Mr. Jensen earned a Master of Fine Arts (MFA) at UCLA Motion Picture Film and Television Producer’s Program (1988) and a Bachelor of Arts (BA) in Biological Sciences at UCSB (1980) magna cum laude. Mr. Jensen is an experienced key executive business manager and entrepreneur with a superlative track record. Mr. Jensen is focused on delivery of social enterprise ventures with competitive financial returns and extraordinary social impact.

Innovative achievements over 35 years (1985-2020) as a CEO/entrepreneur include:

  1. First ever Apple Macintosh multimedia system integrator in Los Angeles (1988-93)
  2. First ever virtual 3D robotic surgery training simulator, tissue realistic, for vascular surgeons (1998)
  3. First ever Norwegian 2D animated feature film, digital ink&paint&composite&film record, co-produced (1998)
  4. First ever mobile app, BBC News content, for Ericsson’s first ever smartphone, on Symbian OS. (1999)
  5. Delivered +50x ROI for investors, including the State of Norway, SND. (2000)
  6. First ever Norwegian 3D animated TV Series for NRK, co-produced (2000)
  7. First ever Norwegian 3D animated Feature Film, co-produced (2006)
  8. First ever Distributed Ledger Technology (DLT) Proof-of-Value delivery for EU Tier-1 Bank (2015)
  9. First ever Vaccine bond to fund-and-find a cure and a vaccine for HIV faster, not-for-profit (2016)
  10. ORION. The Outbreak Response International Open Network, for pro bono global impact (2019)
  11. ECAM. The first ever Biomedical Global Impact Private Equity Fund, based in Guernsey and UK (2019)
  12. ECAM Therapeutics AS. Advanced R&D for Transformative Diagnostics, Clinical Therapies and Vaccines for Infectious Disease and Cancer (2020)

FCA Approved Person

The individual named below is approved under section 59 of the Financial Services and Markets Act (FSMA) 2000 to perform the Controlled Function (set out below and, if applied for, will be noted as responsible for Insurance Distribution):

Individual name: Peter Albert Jensen
Individual Reference Number: PXJ84051

Date of Birth : 17/06/1958
Firm Name                            FRN        Controlled Function(s)     Date(s)
Robert Quinn Advisory LLP   548030   CF1 Director (AR)             16/06/2020
Robert Quinn Advisory LLP   548030   CF30 Customer                 16/06/2020